122 results about "Multiple tumor" patented technology

The invention relates to a liquid phase chip for joint detection of multiple tumor markers and a preparation method thereof. The liquid phase chip comprises micro-balloons of a coupled antibody (at least two of the followings: AFP, CEA, CA125, CA153, CA19-9, CA242, CA72-4, PSA, HGH, Beta-HCG), corresponding biotin-labeled detection antibodies, streptavidin phycoerythrin and vegetable hydrosol or polysaccharide hydrosol which has a solute content of 1-10 wt per thousand and does not contain protein. The preparation of the liquid phase chip comprises refining and purification of hydrosol, coupling between captured antibodies and micro-balloons, preparation of biotin-labeled antibodies, dispersing the coupled micro-balloons into the vegetable hydrosol or the polysaccharide hydrosol, and the like. The liquid phase chip has the advantages of stable performance, good micro-balloon dispersivity, long preservation time, fast and convenient use and operation, small amount of samples in use, high detection sensitivity, wide linear scope and low detection cost, can detect ten tumor markers at most at one time, and requires a cost which is a quarter of the total fee of conventional methods.

The invention provides nonhuman transgenic animals with a disrupted FHIT gene. The invention further provides transgenic mice in which one or both Fhit alleles have been inactivated. Preferably, the Fhit-deficient mice develop multiple tumors of both visceral and sebaceous origin, similar to those of Muir-Torre familial cancer syndrome. The present invention further relates to the generation of these transgenic mice and their use as model systems to study the effects of carcinogenic agents in promoting clonal expansion of neoplastic cells in cancers, preferably gastrointestinal cancers of which Muir-Torre syndrome is a subset. The invention further relates to testing therapeutic agents for their efficacy in the prevention and treatment of cancer, preferably gastrointestinal cancer.

The invention provides nonhuman transgenic animals with a disrupted FHIT gene. The invention further provides transgenic mice in which one or both Fhit alleles have been inactivated. Preferably, the Fhit-deficient mice develop multiple tumors of both visceral and sebaceous origin, similar to those of Muir-Torre familial cancer syndrome. The present invention further relates to the generation of these transgenic mice and their use as model systems to study the effects of carcinogenic agents in promoting clonal expansion of neoplastic cells in cancers, preferably gastrointestinal cancers of which Muir-Torre syndrome is a subset. The invention further relates to testing therapeutic agents for their efficacy in the prevention and treatment of cancer, preferably gastrointestinal cancer.

The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (CDN)—that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM-CSF. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, DC recruitment and proliferation, coupled with a potent DC activation stimulus.

The invention provides nonhuman transgenic animals with a disrupted FHIT gene. The invention further provides transgenic mice in which one or both Fhit alleles have been inactivated. Preferably, the Fhit-deficient mice develop multiple tumors of both visceral and sebaceous origin, similar to those of Muir-Torre familial cancer syndrome. The present invention further relates to the generation of these transgenic mice and their use as model systems to study the effects of carcinogenic agents in promoting clonal expansion of neoplastic cells in cancers, preferably gastrointestinal cancers of which Muir-Torre syndrome is a subset. The invention further relates to testing therapeutic agents for their efficacy in the prevention and treatment of cancer, preferably gastrointestinal cancer.

The invention relates to a self-assembled nano-system of unsaturated fatty acid-anti-tumor drug conjugates as well as a preparation method and application thereof. (1) Unsaturated fatty acid-anti-tumor drug conjugates can be self-assembled in water to form spherical nano-particles with uniform particle sizes and good stability; and (2) in a preparation process, an amphiphilic polymer material such as DSPE-PEG can be optionally added, so that the particle sizes of the self-assembled nano-particles can be further reduced, and the stability of the self-assembled nano-particles can be further enhanced. The self-assembled nano-system of unsaturated fatty acid-anti-tumor drug conjugates, provided by the invention, is simple in preparation method and easy in industrial production and has the advantages of high drug loading capacity, strong stability, good safety and the like; and growth inhibition tests of tumor cells in vitro prove that the self-assembled nano-system has favorable anti-tumor effects on multiple tumor cells.

The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (CDN)—that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of GM-CSF. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, DC recruitment and proliferation, coupled with a potent DC activation stimulus.

The present invention provides an SPR system and corresponding methods of use, for determining the presence or concentration of tumor-associated antigens in cancer patient samples. The SPR system may have multiple channels, with each channel having operably affixed thereto an antibody specific for a tumor-associated antigen, so as to allow detection of multiple tumor-associated antigens simultaneously. When a biological sample from a patient is applied to the SPR system, the presence of two or more tumor-associated antigens can be determined by measuring an SPR signal shift from each channel. The SPR system may detect the presence or concentration of a tumor-associated carbohydrate antigen, where the sensor surface contains affixed thereto an antibody specific for the glycosyl epitope, as well as an antibody specific for the polypeptide to which the carbohydrate antigen is naturally associated in cancer patients.

The invention belongs to the technical field of medicaments and in particular relates to cardiac glycoside compounds with a general formula (I), as well as derivatives, stereoisomers, a racemic mixture or a non-racemic mixture of the stereoisomers and pharmaceutically acceptable acid addition salts or solvates, wherein R1 is CH3, CHO or CH2OH; R2 is H or a linear saccharide chain or a branched saccharide chain, the linear saccharide chain or the branched saccharide chain is formed by saccharides; and these acids comprise inorganic acids like hydrochloric acid, sulfuric acid, hydrobromic acid, phosphoric acid, nitric acid, carbonic acid and the like as well as organic acids like methanoic acid, acetic acid, succinic acid, citric acid, lactic acid, fumaric acid, tartaric acid, benzoic acid, p-methyl-benzenesulfonic acid, methylsulphonic acid, naphthalenesulfonic acid, gluconic acid and the like. The cardiac glycoside compounds can be obtained by separation from plants, in particular Streptocaulon plant juventas or Streptocaulon griffithii, by using multiple conventional separating means or obtained through synthesis, semisynthesis or bioconversion means. These compounds have excellent inhibiting and treatment effects on multiple tumor cells.

The invention provides a substituted diaminopyrimidine compound and medicinal salt thereof. The structure of the substituted diaminopyrimidine compound is as shown in a general formula (I). A pharmacodynamic test proves that the compound is capable of effectively inhibiting growth of multiple tumor cells and can be used for preparing anti-tumor drugs, and meanwhile, the drug resistance of EGFR T790M can be overcome.

The invention relates to a tumor specific target polypeptide and an application thereof. More specifically, the amino acid sequence of the tumor specific target polypeptide provided by the invention is shown by SEQ ID No.1 or 2. After being connected with a polypeptide-amine type dendritic macromolecular nano material, the polypeptide provided by the invention can be perfectly combined with multiple tumor cells in vivo; and as a target agent, the polypeptide has broad application in terms of diagnostic imaging and targeted therapy of tumors.

The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCID mice, but did not target normal blood vessels. This peptide also binds to blood vessels of human lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubicin enhanced the efficacy of the drug against multiple human cancer xenografts in SCID mice.

The invention relates to a double-specific chimeric antigen receptor T cell as well as a preparation method and application thereof. The double-specific chimeric antigen receptor double-specifically targeting human NKG2DL and human CD47 is constructed on the basis of human NKG2D and human SIRPalpha molecules as well as an immune response cell modified with the double-specific chimeric antigen receptor. The novel modified immune response cell can effectively realize targeting attack of multiple tumor cells, particularly positive tumor cells expressing NKG2DL and CD47 and can be used for preparing preparations for treating tumor. The preparation method of the immune response cell modified with the double-specific chimeric antigen receptor double-specifically targeting NKG2DL and CD47 comprises simple steps, the obtained immune response cell modified with the double-specific chimeric antigen receptor double-specifically targeting NKG2DL and CD47 has high specific killing rate for tumor cells.

The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α operably linked to a promoter, wherein the dose comprises about 1×107 to about 4×1012 particle units (pu) of replication-deficient adenoviral vector, at least once in a therapeutic period comprising up to 10 weeks, whereby the cancer in human is treated. The invention further provides a method of treating a human for multiple tumors, wherein the method comprises contacting a first tumor with a dose of the pharmaceutical composition at least once in a therapeutic period comprising up to about 10 weeks, whereby the human is treated for the first tumor and one or more additional tumors.

The invention discloses a fusing protein, encoding gene and appliance, which is characterized by the following: comprising with albuminar and interferon; comprising (a) and (b) protein; choosing amino acid residue sequence from sequences 3 in sequence table as the protein (a); replacing or deleting or adding amino acid residue sequence from sequences 1 trough one or several amino acid residue sequence; possessing interferon alpha 2b active; deriving from the protein (a) as the protein (b). The interferon part of the fusing protein is placed N on end of the fusing protein, but a part of albuminar is placed on the end of C. This fusing protein possesses better homogeneity, higher stability and higher receiving rate, which can be used to cure multiple tumors and virus disease.

The invention belongs to the technical field of medicines, and particularly discloses a composition and a preparation method of cyclic dinucleotide cGAMP (cyclic Guanosine Adenosine Monophosphate) encapsulated by a targeting liposome and application of the cyclic dinucleotide cGAMP to anti-tumor. The targeting liposome consists of lecithin, cholesterol, polyethylene glycol and the like as well as a link targeting molecule of the targeting liposome; a cGAMP slow release drug encapsulated by the targeting liposome can be used for enhancing the intensifying cell osmosis action, enhancing an immune reaction, effectively targeting drug delivery and intensifying the inhibition on the growth of multiple tumor cells. Therefore, the cGAMP encapsulated by the targeting liposome can be used for preparing an anti-tumor targeting slow release drug, and has important potential application in the field of targeting immune anti-tumor.

The invention provides a building method and applications of a living tumor tissue bank. Tumor tissues of a cancerous patient subjected to an operation are transplanted to a part under the renal capsules of SCID (severe combined immunodeficient mice) and survive in the bodies of the mice for passage conservation, so that the living tumor tissue bank is obtained; the living tumor tissue bank means that based on single tumor tissue heterograft, numerous human body tumor tissues are conserved in animal bodies in a living tissue bank form for standby application; the living tumor tissue bank comprises transverse multiple tumors and various subtypes or various development phase of a certain longitudinal tumor. The living tumor tissue bank has multiple applications in the aspects of determining the personalized therapeutic schedule of the cancerous patient subjected to the operation, screening tumor specificities of anti-cancer drugs, and building animal models for human body cancer research.

The invention discloses a 7-oxopyridinopyrimidine compound with a structure shown by formula (I) and a pharmaceutically acceptable salt or a stereoisomer or prodrug molecule thereof. The compound or pharmaceutically acceptable salt provided by the invention can effectively suppress the growth of multiple tumor cells and generate an inhibition effect on other proteases of the Her family of EGFR (epidermal growth factor receptor), can be used for preparing anti-tumor drugs and can overcome the drug resistance induced by the existing drugs gefitinib, erlotinib and the like.

The invention relates to a Bacillus sp.N11-8 and an active component thereof having antitumor action, belonging to the technical field of marine microorganism medicine. The Bacillus sp.N11-8 is obtained by isolated culture in Antarctic Ocean water, and was collected at China Center for Type Culture Collection (Wuhan) on November 19, 2012; and the collection number is CCTCC NO:M2012459. The strain can stably express the active component having antitumor action. The active component has favorable acid / alkali stability and heat stability, and has bigger cytotoxic effect on multiple tumor cells and smaller cytotoxic effect on normal cells of humans. Thus, the Bacillus sp.N11-8 and the active component thereof have favorable research and application values.

An insulated electrode system for delivering a plurality of tumor treating electromagnetic fields including an array of electrode elements for proximate location on a body of a patient. Each electrode element of the array having an insulation layer. Each electrode element being independently electrically accessible and configured to be dynamically assigned to emanate an electromagnetic field relative to at least one other of said electrode elements.

A detection kit of marker substance protein chip for hepatitis B and C as well as multiple type of tumor is prepared as having base plate and reaction holes on it set on reaction hole plate; including 12-200 sample holes and 5-8 standard piece holes in said reaction holes as each reaction hole bottom being set with solid phase carrier; enveloping micro lattice of eight antigen or and body as anti-HBsAg, anti-HCVAg, anti-AFP, anti-CEA, anti-CA199, anti-CA125, anti-PSA and anti-fPSA on said carrier for accurately diagnose said disease in multiple man-share.

The invention discloses an antifolic for anti-tumor therapy, a relative salt and intermediate, wherein the antifolic and relative salt are represented as below, R1=NH2, R2=CH3, or R1=NHCH3 and R2=H, Ar is 1, 4-phenyl or 2, 5-thiofuran, R3 is H, metal cation, ammonium ion, or organic ammonium cation. The invention further discloses an application of the antifolic and relative salt for preparing anti-cancer drug. The inventive antifolic and relative salt have significant growth restraining activity on multiple tumor cells.

The invention discloses baphicacanthus root polysaccharide and a selenized modifier thereof as well as a preparation method and application of the selenized modifier. The disclosed baphicacanthus root polysaccharide is a heteropolysaccharide and consists of mannose, rhamnose, xylose, arabinose and glucose, wherein the ratio of structural units of the five monosaccharides is 2:3:5:6:1. The disclosed selenized modifier refers to baphicacanthus root selenium polysaccharide and is prepared by reacting the baphicacanthus root polysaccharide, organic acid selenide and sulfoxide chloride. The baphicacanthus root selenium polysaccharide prepared based on the baphicacanthus root polysaccharide has an effect of obviously inhibiting multiple tumor cell strains and can be used for preparing medicines for treating cancers.

It is disclosed a method for simultaneous detection of multiple tumor markers, comprising the steps of: (a) mixing analyte samples, a first antibody solution and a second antibody solution, thereby forming a quaternary composite of “Second Antibody-Tumor Marker-First Antibody-bead”; (b) detecting the detectable signals from the distinct beads of the quaternary composites to determine the presence of each tumor marker in the analyte sample. The method of invention can simultaneously detect multiple tumor markers qualitatively or quantitatively. It is also simple, rapid and accurate. The invention also provides the corresponding assay kit.

The invention discloses a construction method and detection method of a trace fragmented DNA methylation detection library. The library construction method of the present invention comprises: linkingfragmented DNA to a methylation linker, wherein all cytosines on the methylation linker are methylated cytosines, the methylation linker includes a long chain and a short chain which are complementaryto form a double chain, and the long chain includes a sequencing platform universal sequence, a single molecule tag sequence, a sample tag sequence and a sequencing primer binding sequence; and the DNA linked with the methylation linker is treated with sodium bisulphate, so that the cytosine C in a non-methylated CpG island is converted into uracil U; and a specific primer and a universal primerare used for PCR amplification enrichment of a target region subjected to sodium bisulfite treatment and containing a CpG site to be detected, so that a library available for on-machine sequencing isobtained. According to the invention, methylation of trace DNA taken through liquid biopsy can be detected, and the CpG island methylation status of multiple regulatory regions of multiple tumor suppressor genes can be quantitatively detected simultaneously.

The invention discloses a method for preparing a cadmium sulfide-coated zinc oxide nano array composite material and a method for detecting multiple tumor cells and relates to a method for preparing the cadmium sulfide-coated zinc oxide nano array composite material and a method of the composite material. Preparation of a nano array material is realized according to chemical deposition, modification and assembly of a nanometer material are realized through the electrostatic interaction, and finally, the synthesized nano array material is applied to preparing a cancer cell biosensor. Moreover, the hepatoma cells are sensitively detected, and the method has the advantages of simplicity in operation, high reaction speed, good effect, high selectivity, low cost and the like. The method also can realize detection of multiple tumor cells by changing the types of the modified antibodies, can be used in aspects such as scientific research and clinical medicine and particularly has wide application prospects in the field of biological analysis and in the aspects such as tumor cell detection.

Disclosed are novel nucleic acid and peptide compositions comprising methythioadenosine phosphorylase (MTAP) and methods of use for MTAP amino acid sequences and DNA segments comprising MTAP in the diagnosis of human cancers and development of MTAP-specific antibodies. Also disclosed are methods for the diagnosis and treatment of tumors and other proliferative cell disorders, and idenification tumor suppressor genes and gene products from the human 9p21-p22 chromosome region. Such methods are useful in the diagnosis of multiple tumor types such as bladder cancer, lung cancer, breast cancer, pancreatic cancer, brain tumors, lymphomas, gliomas, melanomas, and leukemias.

Omics patient data are analyzed using sequences or diff objects of tumor and matched normal tissue to identify patient and disease specific mutations, using transcriptomic data to identify expression levels of the mutated genes, and pathway analysis based on the so obtained omic data to identify specific pathway characteristics for the diseased tissue. Most notably, many different tumors have shared pathway characteristics, and identification of a pathway characteristic of a tumor may thus indicate effective treatment options ordinarily not considered when tumor analysis is based on anatomical tumor type only.

The invention provides a deuterated pyrazolopyrimidine compound, pharmaceutically acceptable salt, stereoisomer, a prodrug molecule or a solvate thereof, a preparation method of the deuterated pyrazolopyrimidine compound, a pharmaceutical composition, a preparation and application. The compound or salt or a pharmaceutical composition and a pharmaceutical preparation thereof have an inhibitory effect on variation forms of EGFR (Epidermal Growth Factor Receptor) protease; production of multiple tumor cells can be effectively inhibited, and the deuterated pyrazolopyrimidine compound can be used for preparing anti-tumor medicines and the like; compared with AZD9291, the compound has the advantages that concentration and stability of the medicine in blood can be improved, so that the use dosageof the medicine can be reduced, and the toxic and side effects of the medicine are reduced.

The invention belongs to the field of medicinal chemistry, and discloses a 3, 6 modified-[1, 2, 4] triazole [3, 4-alpha] phthalazine compound having antitumor activity as well as a synthesizing method and application of the 3, 6 modified-[1, 2, 4] triazole [3, 4-alpha] phthalazine compound. The 3, 6 modified-[1, 2, 4] triazole [3, 4-alpha] phthalazine compound has a structure as shown in a general formula I, wherein R1 refers to H, methyl or phenyl; R2 refers to 4-fluorophenyl, 4-chloroanilino, 4-bromophenyl, 4-methoxyphenyl, 4-hydroxydiphenyl, 2-fluorophenyl, 3-trifluoromethyl)phenyl]amino, naphthylamine-1-yl, pyrrolidone-1-yl, piperidine-1-yl, 3,5-dimethyl piperidine-1-yl, morpholine-4-yl, or piperazidine-1-yl. The preliminary in-vitro antitumor activity finds that the serial compounds have obvious inhibit and killing effects on multiple tumor cells, and the 3, 6 modified-[1, 2, 4] triazole [3, 4-alpha] phthalazine compound can act as an active ingredient to be applied to clinical prevention and cancer treatment after being developed into a novel medicament.